Top 10 Value Stocks To Own Right Now

In this report, we highlight stocks that demonstrate solid growth prospects at a reasonable price (GARP) and provide an update of last month’s report and our January 1 rebalancing note. For older reports, you can visit this link.

Methodology

Our criteria for selecting stocks in these model portfolio strategies, which heavily weight proxies for cash flow growth and ROIC, include the following:

Relative Value Operating Momentum Consensus Estimate Revision Momentum Fundamental Quality

Click to enlargeThe highest ranked stocks are selected for our long model portfolios, and the lowest ranked stocks are selected for our short model portfolios.

Top 10 Value Stocks To Own Right Now: eLong, Inc.(LONG)

Advisors’ Opinion:

  • [By Monica Gerson]

    eLong, Inc. (ADR) (NASDAQ: LONG) is projected to post a quarterly loss at $0.60 per share on revenue of $38.31 million.

    Qunar Cayman Islands Ltd (NASDAQ: QUNR) is expected to post a quarterly loss at $8.89 per share on revenue of $1.11 billion.

Top 10 Value Stocks To Own Right Now: Alexion Pharmaceuticals, Inc.(ALXN)

Advisors’ Opinion:

  • [By David Sterman]

    Growth-oriented investors should also check out Alexion Pharmaceuticals (Nasdaq: ALXN(link is external)), which falls through the cracks between the massive well-established biotechs, and the small-cap biotechs that are still pre-revenue.

    Alexion targets rare and severe diseases, and has built a broad platform of drugs to treat them. Sales growth has never been less than 37% at any point in the past eight years, and 20% to 25% growth appears locked in over coming years as well. Analysts at UBS, who see 30% upside to their $202 price target, believe that a healthy drug pipeline provides multiple catalysts this year in the form of clinical trial updates. They suggest that shares would be worth $230 in a buyout scenario. 

  • [By Ben Levisohn]

    Alexion Pharmaceuticals (ALXN) jumped to the top of the S&P 500 today after Barclays upgraded the biotech stock to Overweight from Equal Weight citing fewer macro headwinds.

    Getty Images

    Shares of Alexion Pharmaceuticals gained 5.2% to $125.59, while the S&P 500 rose 0.1%.

    Barclays analyst Geoff Meacham and team explain why they upgraded Alexion Pharmaceuticals:

    We are upgrading shares ofAlexion to Overweight and increasing our PT to $155 from $150 on an improved outlook for 2017. Specifically, we see lower FX and fewer macroeconomic risks to the core base business over the next 12 months. We also expect approval of Soliris in refractory gMG by YE17 following a planned regulatory submission in 1Q17, which could add another growth lever in early 2018 at the latest. Our upgrade is not a call on the recent 10-Q delay, which according to our discussions with management has to do with an investigation into sales practices following allegations by a former employee. We also do not anticipate major restatements of historical Soliris sales due to the investigation. Furthermore, this is not a call on Kanuma or the Synageva deal, as we have cut our Kanuma sales in our P&L and reduced its contribution in our NPV valuation. Indeed, we would expect minimal weakness inAlexion shares if the company were to take a write-down on Synageva during 2017, but this is not core to our investment thesis. In sum, our bullishness onAlexion shares is due to: 1) lessened FX and macroeconomic headwinds in 2017, 2) near-term Soliris growth from likely regulatory approval in refractory gMG, and 3) attractive upside potential from current levels as the pipeline including line extensions for Soliris and new assets such as 1210 mature.

    Alexion Pharmaceuticals’ market capitalization rose to $28.2 billion today from $26.8 billion yesterday. It reported net income of $144 million on sales of $2.5 billion in 2015.

  • [By Paul Ausick]

    Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) posted a new 52-week low of $98.63 on Wednesday, down about 5.7% compared with Tuesday’s closing price of $04.64. The stock’s 52-week high is $157.02. Volume totaled about 8.5 million shares, around 4 times the daily average of about 3 million. The company announced several executive changes on Tuesday and the fallout has continued.

Top 10 Value Stocks To Own Right Now: FormFactor, Inc.(FORM)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Tuesday, our Elite Opportunity Pronewsletter suggested small cap semiconductor equipment & testing stock FormFactor, Inc (NASDAQ: FORM) as a short term long trade thats a pure small cap play with excellent valuation metrics, in addition to some very attractive chart implications right now:

Top 10 Value Stocks To Own Right Now: Mead Johnson Nutrition Company(MJN)

Advisors’ Opinion:

  • [By Michael Flannelly]

    On Tuesday, JP Morgan analysts upgraded children’s nutrition company Mead Johnson Nutrition (MJN), as they believe the company’s top line growth should be valued more highly than the possible cost headwinds and further Chinese regulations.

    The analysts upgraded MJN from “Neutral” to “Overweight” and see shares reaching $88. This price target suggests a 16% upside to the stock’s Monday closing price of $76.11.

    Mead Johnson Nutrition shares were up 85 cents, or 1.12%, during morning trading on Tuesday. The stock is up 16.71% year-to-date.

  • [By WWW.THESTREET.COM]

    The group agreed to sell its food business to McCormick & Company Inc. (MKC)  last week for $4.2 billion. Reckitt said it would use the sale proceeds to reduce debt, which grew by $21 billion through a pair of financing transactions in March led by Bank of America Merrill Lynch, Deutsche Bank and HSBC in order to fund its $18 billion acquisition of infant nutrition group Mead Johnson (MJN) earlier this year.

Top 10 Value Stocks To Own Right Now: Alliance Data Systems Corporation(ADS)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Alliance Data Systems (ADS) soared to the top of the S&P 500 today after beating the Street’s earnings and revenue expectations.

    Getty Images

    Alliance Data Systemsgained 8.3% to $260.62, while the S&P 500 rose 0.8% to 2,355.84.

    Evercore ISI’s David Togut and team argue that Alliance Data Systems is “checking the right boxes.” They explain:

    ADS’ 1Q/17 earnings reinforced our conviction that net charge offs will stabilize at the end of this year, driving accelerating earnings growth in 2018. Card Services surpassed our revenue and EBITDA forecasts fueled by an 80 basis point increase in gross card yield thanks to rising interest rates. Epsilon’s revenue growth accelerated to 7% from a 1% decline in 4Q/16 driven by double digit growth in Automotive, Agency and digital CRM plus an easy comparison. LoyaltyOne revenue and EBITDA fell below our estimates given soft results from AIR MILES, which is adjusting its value proposition after the Ontario Legislature last December eliminated the expiration date on AIR MILES. Overall, ADS remains on track to generate double-digit adjusted EBITDA and EPS gains in 2017, and in 2018 to accelerate EPS growth to the mid-teens given slowing headwinds from delinquencies plus operating leverage from stabilizing net charge-off rates.

    Alliance Data Systems’ market capitalization rose to $14.6 billion today from $13.5 billion yesterday.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Tuesday was Alliance Data Systems Corp. (NYSE: ADS) which traded down 3.9% at $238.00. The stocks 52-week range is $185.02 to $254.94. Volume was 1.6 million versus the daily average of 577,000 shares.

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Thursday was Alliance Data Systems Corp. (NYSE: ADS) which jumped 8.3% to $260.56. The stocks 52-week range is $185.02 to $263.40. Volume was roughly 1.2 million which is above the daily average of around 606,000 shares.

Top 10 Value Stocks To Own Right Now: FuelCell Energy Inc.(FCEL)

Advisors’ Opinion:

  • [By Peter Graham]

    The Q4 2016 earnings report for small cap fuel cell stockFuelCell Energy Inc (NASDAQ: FCEL) is scheduled forbefore the marketopens onThursday (January 12th). At the beginning of December, FuelCell Energy announced a business restructuring to reduce costs and align production levels with current levels of demand in a manner that is consistent with the Companys long-term strategic plan.The Company said it cut 96 jobs, or 17% of its workforce, and has halved production to 25 megawatts a year in order to position for delays in order flow.The Company alsoexpects to take a $3 million charge in fiscal 2017 related to the job cuts.

  • [By Jim Robertson]

    Fuel cell power solutions stock FuelCell Energy Inc (NASDAQ: FCEL)sank 28.13% after pricing an underwritten public offering of (i) 12,000,000 shares of its common stock, (ii) Series C warrants to purchase 12,000,000 shares of its common stock and (iii) Series D warrants to purchase 12,000,000 shares of its common stock, for gross proceeds of approximately $15.4 million at a public offering price of $1.28 per share and accompanying warrants.However, shares are rising by a double digit percentage in Monday premarket trading:

  • [By Peter Graham]

    The Q1 2017 earnings report for small cap fuel cell stockFuelCell Energy Inc (NASDAQ: FCEL) is scheduled forbefore the marketopens onThursday (March 9th). Last December,FuelCell Energy announced a business restructuring to reduce costs and align production levels with current levels of demand in a manner that is consistent with the Companys long-term strategic plan.The Company said it cut 96 jobs, or 17% of its workforce, and has halved production to 25 megawatts a year in order to position for delays in order flow.

Top 10 Value Stocks To Own Right Now: Burcon Nutrascience Corp(BUR)

Advisors’ Opinion:

  • [By William Romov]

    Last Wednesday (Dec. 6), the company received a patent for certain methods of production of its phase 2 antidepressant, AV-101.

    Penny Stock Current Share Price Dec. 4 – Dec. 8 Gain (as of Dec. 8)
    VistaGen Therapeutics Inc. (Nasdaq: VTGN) $1.80 135%
    FXCM Inc. (Nasdaq: GLBR) $1.12 124%
    Neuralstem Inc. (Nasdaq: CUR) $2.00 75.44%
    Ohr Pharmaceuticals Inc. (Nasdaq: OHRP) $1.49 75.29%
    ClearSign Combustion Corp. (Nasdaq: CLIR) $3.50 53.85%
    Astrotech Corp. (Nasdaq: ASTC) $4.21 51.99%
    Burcon NutraScience Corp. (Nasdaq: BUR) $0.72 44%
    LM Funding America Inc. (Nasdaq: LMFA) $3.72 42.53%
    Second Sight Medical Products Inc. (Nasdaq: EYES) $1.75 42.28%
    Globus Maritime Ltd. (Nasdaq: GLBS) $1.47 41.35%

    As a result, its share price shot up from $0.92 to $2.52 on Wednesday. The stock pulled back to $1.80 by the end of the week, for a total gain of 135% for the week.

Top 10 Value Stocks To Own Right Now: MGE Energy Inc.(MGEE)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Wednesday, utilities shares fell by 0.75 percent. Meanwhile, top losers in the sector included California Water Service Group (NYSE: CWT), down 7 percent, and MGE Energy, Inc. (NASDAQ: MGEE), down 6 percent.

Top 10 Value Stocks To Own Right Now: Leading Brands Inc(LBIX)

Advisors’ Opinion:

  • [By Lisa Levin]

    Leading Brands, Inc (USA) (NASDAQ: LBIX) shares shot up 66 percent to $2.49 following Q1 results. Leading Brands reported Q1 earnings of $0.10 per share on revenue of $3.033 million.

  • [By Lisa Levin]

    Leading Brands, Inc (USA) (NASDAQ: LBIX) shares dropped 13 percent to $1.99 following Q2 results. Leading Brands posted Q2 EBITDAS of $0.00 per share, compared to $0.09 per share during the same period last year.

  • [By Lisa Levin]

    Leading Brands, Inc (USA) (NASDAQ: LBIX) shares were also up, gaining 145 percent to $3.31 on no formal news from company. The stock rallied 215 percent over Tuesday and Wednesday of this week amid trader speculation stock could be sympathy play on move higher in Helios & Matheson. However, Leading Brands shares sold off 27 percent on Thursday.

Top 10 Value Stocks To Own Right Now: TheStreet, Inc.(TST)

Advisors’ Opinion:

  • [By Steven Goldberg]

    Launched in August 2001, Action Alerts PLUS Portfolio has been a centerpiece of the financial advice offered by TheStreet.com. The website belongs to TheStreet, Inc. (TST), a publicly traded company that Cramer co-founded in 1996. PLUS Portfolio subscribers, who pay $15 a month, always get the recommendations before Cramer buys them for the portfolio, the Wharton paper reports. Likewise, subscribers get Cramers picks before he airs them on Mad Money.

  • [By Lisa Levin] Companies Reporting Before The Bell
    Tyson Foods, Inc. (NYSE: TSN) is expected to report quarterly earnings at $1.38 per share on revenue of $9.86 billion.
    Aecom (NYSE: ACM) is projected to report quarterly earnings at $0.71 per share on revenue of $4.67 billion.
    JD.Com Inc(ADR) (NASDAQ: JD) is estimated to report quarterly earnings at $0.11 per share on revenue of $12.60 billion.
    58.com Inc (ADR) (NYSE: WUBA) is projected to report quarterly earnings at $0.28 per share on revenue of $383.60 million.
    Kamada Ltd (NASDAQ: KMDA) is expected to report quarterly earnings at $0.02 per share on revenue of $25.00 million.
    Palatin Technologies, Inc. (NYSE: PTN) is projected to report quarterly earnings at $0.06 per share on revenue of $28.00 million.
    TheStreet, Inc. (NASDAQ: TST) is estimated to report a quarterly loss at $0.02 per share on revenue of $15.81 million.
    Atlantica Yield PLC (NASDAQ: ABY) is projected to report quarterly earnings at $0.45 per share on revenue of $290.80 million.
    Asure Software Inc (NASDAQ: ASUR) is estimated to report quarterly earnings at $0.15 per share on revenue of $15.26 million.
    Cyren Ltd (NASDAQ: CYRN) is expected to report quarterly loss at $0.06 per share on revenue of $7.90 million.
    Viewray Inc (NASDAQ: VRAY) is estimated to report quarterly loss at $0.12 per share on revenue of $18.58 million.

     

Leave a Reply

Your email address will not be published. Required fields are marked *